Clinical Oncology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Fourth Military Medical University provide details of new studies and findings in the area of cancer gene therapy
May 12th, 2008
"Bcl-xL, a novel member of anti-apoptotic Bcl-2 family that play important roles in regulating cell survival and apoptosis, is frequently overexpressed in various kinds of human cancers, including prostatic carcinoma. To explore its possibility as a therapeutic target for prostatic carcinoma, we developed a novel tumor-specific RNA interference system by using survivin promoter and employed it to suppress exogenous reporters (LUC and EGFP) and endogenous gene Bcl-xL expression and analyzed its phenotypes," scientists in Xian, People's Republic of China report. "We found that expression of exogenous reporters (LUC and EGFP) was specifically inhibited in tumor cells but not...
Source: Clinical Oncology Week (2008-05-12)
|
